MaxCyte: Selling ExPERT Cell Engineering Platforms
Former Midwest Sales Manager at MaxCyte
inpractise.com/articles/maxcyte-selling-expert-flow-electroporation-machines
MaxCyte Inc
Why is this company interesting?
MaxCyte is a leading cell engineering platform technology to support cell therapeutic discovery, development, and commercialisation. MaxCyte’s ExPERT platform is the leading technology for non-viral ex vivo cell therapy, a market that is forecasted to grow to over $24bn by 2026.
Over the last 20 years, MaxCyte has been developing flow electroporation methods of transfection and is still operated and minority owned by the founder. The company has ~40% market share in US non-viral clinical programs and the ExPERT platforms offer better transfection rates and a faster route to clinic for customers relative to Lonza or Thermo Fisher’s competing solutions.
The company has 13 customers on strategic platform licenses where MXCT receives a recurring instrument license and consumable income per year plus a percentage of sales once the therapy is commercialised. MaxCyte is the highest-quality non-viral cell engineering globally that is positioned to be the platform provider for the future for ex vivo cell therapies.
MaxCyte: Selling ExPERT Cell Engineering Platforms(October 1, 2021)
Michael Carlson
Former Midwest Sales Manager at MaxCyte
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Related Content
Maxcyte's Technology, Pricing, & Growth Outlook
Former Midwest Sales Manager at MaxCyte
MaxCyte: Electroporation Technology, Cell & Gene Therapy & Competition
Former Business Development Technical Expert at MaxCyte
AWS Series: Kubernetes & The Portability Illusion
Burford & Elliott vs Argentina, CACC, SHEIN, Smurfit / WestRock, MaxCyte, Alteryx
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.